Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore

References

• Ministry of Health, Singapore; n.d.; available from https://www.moh.gov.sg/content/moh_web/home/diseases_and_conditions/h/hiv_aids.html
   Google Scholar
• Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recommendations Reports 2010; 59:1-62
   PubMedGoogle Scholar
• Hazenberg MD, Hamann D, Schuitemaker H, Miedema F. T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol 2000; 1:285-9; PMID:11017098; http://dx.doi.org/10.1038/79724
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Teruya K, Tanaka M, Kikuchi Y, Takahashi T, Kimura S, Oka S, HIV/Influenza Vaccine Study Team. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 39:167-73; PMID:15905732
   PubMed Web of Science ®Google Scholar
• Tebas P, Frank I, Lewis M, Quinn J, Zifchak L, Thomas A, Kenney T, Kappes R, Wagner W, Maffei K, et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010; 24:2187-92; PMID:20616698; http://dx.doi.org/10.1097/QAD.0b013e32833c6d5c
   PubMed Web of Science ®Google Scholar
• Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS 1994; 8:469-76; PMID:7912086; http://dx.doi.org/10.1097/00002030-199404000-00008
   PubMed Web of Science ®Google Scholar
• Fuller JD, Craven DE, Steger KA, Cox N, Heeren TC, Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 1999; 28:541-7; PMID:10194075; http://dx.doi.org/10.1086/515170
   PubMed Web of Science ®Google Scholar
• Günthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, Hwang J, Haubrich R, Havlir D, Richman DD. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 2000; 181:522-31; PMID:10669335; http://dx.doi.org/10.1086/315260
   PubMed Web of Science ®Google Scholar
• Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000; 18:3040-9; PMID:10825608; http://dx.doi.org/10.1016/S0264-410X(00)00079-7
   PubMed Web of Science ®Google Scholar
• Machado AA, Machado CM, Boas LSV, Lopes MC, Gouvêa A de FB, Succi RC de M, Mendoza TRT, Kanashiro TM, Machado DM. Short communication: immunogenicity of an inactivated influenza vaccine and postvaccination influenza surveillance in HIV-infected and noninfected children and adolescents. AIDS Res Hum Retroviruses 2011; 27:999-1003; PMID:21284525; http://dx.doi.org/10.1089/aid.2010.0306
   PubMed Web of Science ®Google Scholar
• Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013; 19:1597-608; PMID:24309663; http://dx.doi.org/10.1038/nm.3409
   PubMed Web of Science ®Google Scholar
• Lamere MW, Moquin A, Lee FE-H, Misra RS, Blair PJ, Haynes L, Randall TD, Lund FE, Kaminski DA. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol 2011; 85:5027-35; PMID:21367900; http://dx.doi.org/10.1128/JVI.00150-11
   PubMed Web of Science ®Google Scholar
• Corsini E, Vismara L, Lucchi L, Viviani B, Govoni S, Galli CL, Marinovich M, Racchi M. High interleukin-10 production is associated with low antibody response to influenza vaccination in the elderly. J Leukoc Biol 2006; 80:376-82; PMID:16707559; http://dx.doi.org/10.1189/jlb.0306190
   PubMed Web of Science ®Google Scholar
• Klein MB, Lu Y, DelBalso L, Coté S, Boivin G. Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis 2007; 45:234-40; PMID:17578785; http://dx.doi.org/10.1086/518986
   PubMed Web of Science ®Google Scholar
• King JC, Fast PE, Zangwill KM, Weinberg GA, Wolff M, Yan L, Newman F, Belshe RB, Kovacs A, Deville JG, et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001; 20:1124-31; PMID:11740317; http://dx.doi.org/10.1097/00006454-200112000-00006
   PubMed Web of Science ®Google Scholar
• King J, Treanor J, Fast P, Wolff M, Yan L, Iacuzio D, Readmond B, O'Brien D, Mallon K, Highsmith W, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000; 181:725-8; PMID:10669363; http://dx.doi.org/10.1086/315246
   PubMed Web of Science ®Google Scholar
• Levin MJ, Song L-Y, Fenton T, Nachman S, Patterson J, Walker R, Kemble G, Allende M, Hultquist M, Yi T, et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 2008; 26:4210-7; PMID:18597900; http://dx.doi.org/10.1016/j.vaccine.2008.05.054
   PubMed Web of Science ®Google Scholar
• Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, Clements ML. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989; 262:779-83; PMID:2787416; http://dx.doi.org/10.1001/jama.1989.03430060075029
   PubMed Web of Science ®Google Scholar
• Cooper C, Thorne A, Klein M, Conway B, Boivin G, Haase D, Shafran S, Zubyk W, Singer J, Halperin S, et al. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One 2011; 6:e17758; PMID:21512577; http://dx.doi.org/10.1371/journal.pone.0017758
   PubMed Web of Science ®Google Scholar
• Harrington DG, Crabbs CL, Hilmas DE, Brown JR, Higbee GA, Cole FE, Levy HB. Adjuvant effects of low doses of a nuclease-resistant derivative of polyinosinic acid. polycytidylic acid on antibody responses of monkeys to inactivated venezuelan equine encephalomyelitis virus vaccine. Infect Immun 1979; 24:160-6; PMID:110688
   PubMed Web of Science ®Google Scholar
• Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 2002; 169:4905-12; PMID:12391202; http://dx.doi.org/10.4049/jimmunol.169.9.4905
   PubMed Web of Science ®Google Scholar
• Lau YF, Tang L-H, McCall AW, Ooi EE, Subbarao K. An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice. J Virol 2010; 84:8639-49; PMID:20538850; http://dx.doi.org/10.1128/JVI.00596-10
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Weeratna RD, Krieg AM, Davis HL. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 2000; 19:950-7; PMID:11115721; http://dx.doi.org/10.1016/S0264-410X(00)00215-2
   PubMed Web of Science ®Google Scholar
• Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, Rosenthal KL. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 2001; 166:3451-7; PMID:11207303; http://dx.doi.org/10.4049/jimmunol.166.5.3451
   PubMed Web of Science ®Google Scholar
• Pape KA, Khoruts A, Mondino A, Jenkins MK. Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J Immunol 1997; 159:591-8; PMID:9218573
   PubMed Web of Science ®Google Scholar
• Curtsinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, Mescher MF. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 1999; 162:3256-62; PMID:10092777
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3:133-46; PMID:12563297; http://dx.doi.org/10.1038/nri1001
   PubMed Web of Science ®Google Scholar
• Stahl-Hennig C, Eisenblätter M, Jasny E, Rzehak T, Tenner-Racz K, Trumpfheller C, Salazar AM, Uberla K, Nieto K, Kleinschmidt J, et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 2009; 5:e1000373; PMID:19360120; http://dx.doi.org/10.1371/journal.ppat.1000373
   PubMed Web of Science ®Google Scholar
• Deng Y, Jing Y, Campbell AE, Gravenstein S. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol 2004; 172:3437-46; PMID:15004143; http://dx.doi.org/10.4049/jimmunol.172.6.3437
   PubMed Web of Science ®Google Scholar
• Maue AC, Eaton SM, Lanthier PA, Sweet KB, Blumerman SL, Haynes L. Proinflammatory adjuvants enhance the cognate helper activity of aged CD4 T cells. J Immunol 2009; 182:6129-35; PMID:19414765; http://dx.doi.org/10.4049/jimmunol.0804226
   PubMed Web of Science ®Google Scholar
• Gelman AE, Zhang J, Choi Y, Turka LA. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 2004; 172:6065-73; PMID:15128790; http://dx.doi.org/10.4049/jimmunol.172.10.6065
   PubMed Web of Science ®Google Scholar
• Haynes L, Eaton SM, Burns EM, Rincon M, Swain SL. Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo. J Immunol 2004; 172:5194-9; PMID:15100256; http://dx.doi.org/10.4049/jimmunol.172.9.5194
   PubMed Web of Science ®Google Scholar
• Launay O, Desaint C, Durier C, Loulergue P, Duval X, Jacomet C, Pialoux G, Ghosn J, Raffi F, Rey D, et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis 2011; 204:124-34; PMID:21628666; http://dx.doi.org/10.1093/infdis/jir211
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Di Giambenedetto S, Sali M, Farina S, Sansonetti P, Tamburrini E, Dal Verme LZ, Delogu G, De Luca A, Kelvin D, et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine 2011; 29:2836-9; PMID:21349364; http://dx.doi.org/10.1016/j.vaccine.2011.02.020
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, Krieg AM, Cameron DW. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005; 19:1473-9; PMID:16135900; http://dx.doi.org/10.1097/01.aids.0000183514.37513.d2
   PubMed Web of Science ®Google Scholar
• Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008; 46:1310-4; PMID:18444872; http://dx.doi.org/10.1086/533467
   PubMed Web of Science ®Google Scholar
• Murphy BR, Phelan MA, Nelson DL, Yarchoan R, Tierney EL, Alling DW, Chanock RM. Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol 1981; 13:554-60; PMID:7240388
   PubMed Web of Science ®Google Scholar
• Murphy BR, Kasel JA, Chanock RM. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 1972; 286:1329-32; PMID:5027388; http://dx.doi.org/10.1056/NEJM197206222862502
   PubMed Web of Science ®Google Scholar
• Schulman JL, Khakpour M, Kilbourne ED. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 1968; 2:778-86; PMID:5701819
   PubMed Web of Science ®Google Scholar
• Chen Z, Yoshikawa T, Kadowaki S, Hagiwara Y, Matsuo K, Asanuma H, Aizawa C, Kurata T, Tamura S. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J Gen Virol 1999; 80(Pt 10):2559-64; PMID:10573147; http://dx.doi.org/10.1099/0022-1317-80-10-2559
   PubMed Web of Science ®Google Scholar
• García-Cañas V, Lorbetskie B, Bertrand D, Cyr TD, Girard M. Selective and quantitative detection of influenza virus proteins in commercial vaccines using two-dimensional high-performance liquid chromatography and fluorescence detection. Anal Chem 2007; 79:3164-72; http://dx.doi.org/10.1021/ac0621120
   PubMed Web of Science ®Google Scholar
• Hakim H, Allison KJ, Van De Velde LA, Li Y, Flynn P, McCullers JA. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults. Vaccine 2011; 30(5):885
   Google Scholar
• Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 2002; 20 Suppl 5:B29-32; http://dx.doi.org/10.1016/S0264-410X(02)00511-X
   Google Scholar
• Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 2001; 25:386-401; PMID:11846608; http://dx.doi.org/10.1006/meth.2001.1261
   PubMed Web of Science ®Google Scholar